Hairy cell leukemia is a rare hematological malignancy that affects the blood, bone marrow, spleen, and other organs. First described in the late 1950s, the disease is characterized by the overgrowth of abnormal white blood cells, which crowds out the production of normal blood cells and leaves patients vulnerable to infection, anemia, and bleeding complications. The cancer takes its name from a striking microscopic feature: the malignant cells carry short, thin, hair-like projections on their surface, giving them an unmistakable appearance under the microscope. Approximately 1,200 Americans receive a diagnosis each year, and for reasons that remain unknown, men are affected four times more often than women.

One of the most important conceptual advances in recent years has been the recognition that hairy cell leukemia is not a single disease but two distinct entities: classic hairy cell leukemia and hairy cell leukemia variant. Classic disease is by far the more common form, accounting for up to 90 percent of cases. Thanks to current treatments, most patients with classic hairy cell leukemia remain in remission for five to 15 years or more, a remarkable achievement for a blood cancer that once carried a grim prognosis. Variant disease, by contrast, is far more aggressive. Roughly 10 to 15 percent of patients have the variant form, which tends to respond less well to therapy, relapses more quickly, and carries a poor survival rate. Patients with classic disease who relapse also face a much worse outlook. Closing this gap between the success achieved in classic disease and the unmet needs of variant and relapsed patients is the central focus of the latest round of grants.

The six new awards zero in on a range of aspects of the disease, supporting patients from initial diagnosis and throughout their treatment. At The Ohio State University, Christopher Oakes, Ph.D., is working to advance understanding and classification of hairy cell leukemia in individual patients. Precise classification is the essential first step in ensuring that each patient receives the right treatment, particularly in a rare cancer where expertise is concentrated at a limited number of centers. At Dana-Farber Cancer Institute in Boston, Gregory Abel, M.D., M.P.H., is examining quality of life, decision-making, and outcomes for patients, acknowledging that survival is only one measure of success in a chronic disease that can require repeated courses of therapy.

At Stanford University in California, Gerlinde Wernig, M.D., is focused on finding new methods to improve disease prognosis, including understanding the factors that lead to relapse and to the development of variant disease. Her work addresses one of the deepest questions in the field: why some patients respond beautifully to treatment while others progress to more aggressive forms. At Case Western Reserve University in Cleveland, Reshmi Parameswaran, Ph.D., is examining how hairy cell leukemia becomes resistant to treatment and developing new therapeutic strategies for the variant form. Drug resistance is a central mechanism behind relapse, and unraveling it at the molecular level could open the door to treatments that overcome or prevent it.

Two of the grants support clinical trials testing combination therapies in Europe. Enrico Tiacci, M.D., at the University of Perugia in Italy, will be testing an all-oral combination treatment for patients whose hairy cell leukemia has relapsed. Tiacci’s involvement in this partnership is not new: his groundbreaking earlier work, also supported by research funds from this collaboration, established the drug vemurafenib as an alternative to the chemotherapy-based standard of care. Vemurafenib targets the BRAF mutation that drives the vast majority of classic hairy cell leukemia cases, and its success transformed the treatment landscape for relapsed patients who had exhausted conventional options.

Across the Atlantic, Francesco Forconi, M.D., Ph.D., at the University of Southampton in the United Kingdom, is testing whether a combination of two drugs that inhibit different proteins involved in hairy cell leukemia can produce deep, long-lasting remissions. The ambition behind his trial is a fixed-duration treatment paradigm: patients would stop therapy after a defined period and remain in remission, rather than having to take treatment indefinitely. For a rare cancer where patients may live for decades with their disease, the difference between lifelong therapy and a finite course with durable remission is profound, both medically and in terms of quality of life.

The scale and coordination of the HCL2030 program reflect a deliberate strategy for a rare disease. Because hairy cell leukemia affects relatively few patients, no single institution sees enough cases to drive major advances alone. Lore Gruenbaum, Ph.D., chief scientific officer at Blood Cancer United, emphasized this point, noting that medical research is not a solo sport. Even though researchers are working at different locations across two continents, she said, they are all very much on the same team, and that cooperation is particularly important for rare diseases such as hairy cell leukemia. It takes cooperation, time, and money, she added, to find the advances that will make a real difference for patients.

Anna Lambertson, executive director of the Hairy Cell Leukemia Foundation, framed the grants as the direct result of patient and family commitment to the cause. For patients with classic hairy cell leukemia, she noted, the field has achieved years and often decades of remission. Patients with variant disease, and those who relapse, deserve treatments that work just as well, she said, describing the grants as the way to close that gap. The Hairy Cell Leukemia Foundation, founded in 1984, is the only United States nonprofit solely focused on the disease. Founded and governed by patients, it funds innovative research, advances education, and provides peer support worldwide, and its patient-led mission has helped drive major treatment advances over four decades.

Blood Cancer United, the largest global nonprofit focused on blood cancer patient support, research, and advocacy, has served people affected by more than 100 types of blood cancer since its founding in 1949. The organization funds innovative research, offers free resources and personalized support, and advocates for more accessible and affordable healthcare for all patients. Together, the two organizations have turned the HCL2030 program into a coordinated engine for progress in a cancer that receives little attention relative to its impact on those it affects. With nearly $7 million in new investment now flowing to laboratories and clinics in the United States and Europe, the next five years promise advances in classification, prognosis, drug resistance, and treatment duration that could reshape the outlook for every hairy cell leukemia patient, particularly those with variant disease or relapse who have waited longest for options equal to those enjoyed by the majority.

Subject of Research: New research funding for hairy cell leukemia diagnosis, prognosis, and therapy development

Article Title: Nearly $7 million in new funding accelerates hairy cell leukemia research

Article References: Nearly $7 million in new funding accelerates hairy cell leukemia research. (n.d.). Original publication

Image Credits: AI Generated

DOI: Not provided

Keywords: hairy cell leukemia, Blood Cancer United, Hairy Cell Leukemia Foundation, HCL2030, blood cancer research grants, variant hairy cell leukemia, vemurafenib, drug resistance, relapse, rare disease funding, combination therapy, all-oral treatment

The new study, published in the Journal of Experimental & Clinical Cancer Research, centers on BRN2, a transcription factor encoded by the POU3F2 gene. Transcription factors are proteins that bind to DNA and switch other genes on or off, and BRN2 has long been associated with aggressive, invasive melanoma behavior. Previous work had hinted at a connection between BRN2 and anoikis resistance, but the precise signaling cascade through which BRN2 keeps suspended cells alive remained unknown. The research team, led by Hannah M. Neuendorf, Jacinta L. Simmons and Glen M. Boyle, spanning QIMR Berghofer Medical Research Institute, Queensland University of Technology and the University of Queensland, set out to close that gap using an unusually powerful combination of genetic screening, chemical probes and proteomic analysis.

To confirm that BRN2 genuinely drives anoikis resistance rather than merely correlating with it, the investigators deployed genome-wide CRISPR screens. These screens use the CRISPR gene-editing machinery in two complementary modes: CRISPR activation, which ramps up gene expression, and CRISPR inhibition, which dials it down using a nuclease-dead form of the Cas9 protein fused to repressive domains. By applying these screens to human melanoma cell lines grown in ultra-low attachment plates, conditions that force cells to survive without their usual anchoring to the extracellular matrix, the researchers could see which genes helped or hindered survival in suspension. The results validated BRN2 as a bona fide driver of anoikis resistance. When BRN2 was suppressed, melanoma cells that had previously shrugged off detachment became markedly more sensitive to death by anoikis.

Genetic validation alone, however, does not yield a drug. The team therefore turned to small molecule inhibitors designed to bind the BRN2 protein directly. These chemical probes, referred to in the study as B18 and B18-94, were synthesized and characterized in detail, including nuclear magnetic resonance spectra and crystallographic analysis of their structures. In melanoma cell lines with acquired anoikis resistance, treatment with the inhibitors restored sensitivity to anoikis under ultra-low attachment conditions. The effect was measured by flow cytometry, with cells stained with propidium iodide and calcein dyes to distinguish living from dying populations over seven days in suspension culture. Across multiple resistant cell lines, including MM383, C-32 and MM386, the compounds substantially reduced the fraction of cells that survived detachment.

To understand what BRN2 inhibition actually does inside the cell, the researchers used the small molecules as probes for quantitative mass spectrometry, a technique that measures the abundance of thousands of proteins simultaneously. The proteomic fingerprints that emerged pointed squarely at the mitochondria, the membrane-bound organelles that generate most of a cell’s chemical energy. BRN2 inhibition increased oxidative phosphorylation, the mitochondrial energy-production process, and raised the expression of a protein called AIFM2. The consequence was apoptosis, the standard cellular suicide program, accompanied by mitochondrial fragmentation, a physical collapse of the organelle’s normal tubular network into disconnected pieces. In other words, BRN2 appears to keep suspended melanoma cells alive by promoting a state of mitochondrial dysfunction that somehow shields them from apoptotic signals, and removing BRN2 dismantles that protection.

The study also traced the upstream wiring. According to the authors, BRN2 drives anoikis resistance through the MAPK and NF-κB signaling pathways, which leads to dysregulation of PPARγ, a nuclear receptor involved in metabolism and cell fate. This signaling chain ultimately produces the mitochondrial changes observed in the proteomics data. The team also examined STAT3, another signaling protein implicated in melanoma survival, and measured changes in its phosphorylation state following inhibitor treatment. Together, these findings sketch a coherent circuit: an anchorage-independent cell relies on BRN2-dependent transcriptional programs to keep its mitochondria in a configuration that permits survival, and disrupting BRN2 collapses that program from the top down.

Perhaps the most clinically significant result involves vemurafenib, a BRAF inhibitor that transformed treatment for melanoma patients carrying BRAF mutations but whose benefits are often eroded by resistance. When the researchers combined BRN2 inhibitors with vemurafenib, the melanoma cells became significantly more sensitive to killing by the BRAF-targeted drug. Synergy assays, analyzed using the Highest Single Agent model, demonstrated that the combination was more effective than either treatment alone, both in standard adherent culture and in ultra-low attachment conditions that mimic the suspension phase of metastasis. For the first time in melanoma models, the study shows that pharmacological inhibition of BRN2 can sensitize cells to BRAF-targeted therapy, suggesting a potential strategy for extending the reach of existing medicines.

The implications extend beyond drug combination. Because anoikis resistance is thought to be essential for cancer cells to survive the journey from a primary tumor to a distant site, a therapy that reverses this resistance could theoretically prevent the seeding of metastatic disease before it begins. The researchers note that inhibiting BRN2 may block metastasis at one of its most vulnerable steps, the period when circulating tumor cells are unanchored and exposed. That idea remains to be tested in clinical settings, and the compounds used in this study are research probes rather than approved medicines. Nonetheless, the demonstration that a transcription factor once considered undruggable can be chemically inhibited with functional consequences opens a path that many in the field had regarded as difficult.

The work also carries broader lessons for cancer biology. Anoikis resistance is not unique to melanoma; it is a hallmark of many carcinomas and contributes to tumor formation and progression across cancer types. By identifying mitochondrial dysfunction as the mechanistic bridge between BRN2 activity and survival in suspension, the study adds to a growing body of evidence that metabolic state and cell death sensitivity are deeply intertwined. It also showcases a methodological template: genome-wide CRISPR screens to find the driver, selective small molecules to interrogate and disable it, and quantitative proteomics to map the downstream consequences. The research was supported by an Australian Government Research Training Program Scholarship and a philanthropic donation from Brian and Merle Dwyer, and the authors report no competing interests. As the scientific community awaits follow-up studies in animal models and, eventually, clinical candidates, the message of this work is clear: the molecular machinery that lets melanoma cells travel unafraid through the body can be targeted, and doing so may render one of medicine’s most stubborn cancers considerably more defenseless.

Subject of Research: BRN2-driven anoikis resistance in melanoma and its reversal by small molecule inhibitors

Article Title: Inhibition of BRN2 in melanoma reverses anoikis resistance and sensitizes cells to killing by vemurafenib

Article References: Neuendorf, H. M., He, X., Adams, M. N., Chow, S., Tran, K. A., Smith, A. G., Bernhardt, P. V., Williams, C. M., Simmons, J. L., & Boyle, G. M. (2026). Inhibition of BRN2 in melanoma reverses anoikis resistance and sensitizes cells to killing by vemurafenib. Journal of Experimental & Clinical Cancer Research. https://doi.org/10.1186/s13046-026-03819-y

Image Credits: AI Generated

DOI: 10.1186/s13046-026-03819-y

Keywords: melanoma, BRN2, anoikis resistance, vemurafenib, CRISPR screens, mitochondria, metastasis, targeted therapy, AIFM2, BRAF inhibitor, transcription factor, proteomics